Disseminated Intravascular Coagulation

Back

Background

Disseminated intravascular coagulation (DIC) is characterized by systemic activation of blood coagulation, which results in generation and deposition of fibrin, leading to microvascular thrombi in various organs and contributing to multiple organ dysfunction syndrome (MODS).[1, 2]  Consumption of clotting factors and platelets in DIC can result in life-threatening hemorrhage.[3]

Derangement of the fibrinolytic system further contributes to intravascular clot formation, but in some cases, accelerated fibrinolysis may cause severe bleeding. Hence, a patient with DIC can present with a simultaneously occurring thrombotic and bleeding problem, which obviously complicates the proper treatment.

The subcommittee on DIC of the International Society on Thrombosis and Haemostasis has suggested the following definition for DIC: “An acquired syndrome characterized by the intravascular activation of coagulation with loss of localization arising from different causes. It can originate from and cause damage to the microvasculature, which if sufficiently severe, can produce organ dysfunction.”[4]

DIC is estimated to be present in as many as 1% of hospitalized patients.[5] DIC is not itself a specific illness; rather, it is a complication or an effect of the progression of other illnesses. It is always secondary to an underlying disorder and is associated with a number of clinical conditions, generally involving activation of systemic inflammation. Such conditions include the following[6] :

DIC is most commonly observed in severe sepsis and septic shock. Indeed, the development and severity of DIC correlate with mortality in severe sepsis.[10, 11] Although bacteremia, including both gram-positive and gram-negative organisms, is most commonly associated with DIC, other organisms (eg, viruses, fungi, and parasites) may also cause DIC.

Trauma, especially neurotrauma, is also frequently associated with DIC. DIC is more frequently observed in trauma patients with the systemic inflammatory response syndrome (SIRS).[12] Evidence indicates that inflammatory cytokines play a central role in DIC in both trauma patients and septic patients. In fact, the systemic cytokine profiles in septic patients and trauma patients are nearly identical.[13]

The symptoms of DIC are often those of the underlying inciting condition (see Etiology). In addition, symptoms of thrombosis, embolism, organ dysfunction, or bleeding may be present.

Acute versus chronic DIC

DIC exists in both acute and chronic forms. Acute DIC develops when sudden exposure of blood to procoagulants (eg, tissue factor [TF], or tissue thromboplastin) generates intravascular coagulation. Compensatory hemostatic mechanisms are quickly overwhelmed, and, as a consequence, a severe consumptive coagulopathy leading to hemorrhage develops. Abnormalities of blood coagulation parameters are readily identified, and organ failure frequently results.

In contrast, chronic DIC reflects a compensated state that develops when blood is continuously or intermittently exposed to small amounts of TF. Compensatory mechanisms in the liver and bone marrow are not overwhelmed, and there may be little obvious clinical or laboratory indication of the presence of DIC. Chronic DIC is more frequently observed in patients with solid tumors and in those with large aortic aneurysms.[14]

Pathophysiology

The hematologic derangements seen in DIC result from the following 4 simultaneously occurring mechanisms[15, 16] :

Thrombin generation and tissue factor

Thrombin generation is detectable at 3-5 hours after the occurrence of bacteremia or endotoxemia. Ample evidence exists for a pivotal role of the TF/factor VIIa system in the initiation of thrombin generation.[17, 18, 19]

Exposure to TF in the circulation occurs via endothelial disruption, tissue damage, or inflammatory or tumor cell expression of procoagulant molecules (including TF). TF activates coagulation via the extrinsic pathway involving factor VIIa. The TF-VIIa complex activates thrombin, which cleaves fibrinogen to fibrin while simultaneously causing platelet aggregation. The intrinsic (or contact) pathway may also be activated in DIC, though contributing more to hemodynamic instability and hypotension than to activation of clotting.[20]

Thrombin produced by the TF/factor VII pathway amplifies both clotting and inflammation through the following activities[21] :

Factor VIIa has been implicated as the central mediator of intravascular coagulation in sepsis. Blocking the factor VIIa pathway in sepsis has been shown to prevent the development of DIC, whereas interrupting alternative pathways did not demonstrate any effect on clotting.[22, 23]

Abrogation of the TF/factor VII(a) pathway by monoclonal antibodies specifically directed against TF or factor VIIa activity completely inhibited of thrombin generation in endotoxin-challenged chimpanzees and prevented the occurrence of DIC and mortality in baboons that were infused with Escherichia coli. Indeed, in most DIC patients, TF antigen is detectable in plasma. Hence, activation of coagulation in DIC is primarily TF-driven; the intrinsic pathway of coagulation appears not to play an important role.

The actual source of the TF has not been established with certainty. TF may be expressed on mononuclear cells in vitro, and its expression on circulating monocytes of patients with severe infection has been demonstrated. In addition, it may be expressed on endothelial cells. Injured endothelial cells express TF, whereas healthy ones do not. However, the importance of endothelial cell TF expression in vivo and its role in the pathogenesis of DIC remain to be determined.

Another source of TF may be polymorphonuclear leukocytes (PMNs) and other similar cell types, though it is unlikely that these cells actually synthesize TF in substantial quantities. On the basis of the observation that TF has been transferred from leukocytes to activated platelets on a collagen surface in an ex-vivo perfusion system, it is hypothesized that this “bloodborne” TF is transferred between cells through microparticles derived from activated mononuclear cells.

Impaired coagulation inhibitor systems

Thrombin generation is usually tightly regulated by multiple hemostatic mechanisms. However, once intravascular coagulation commences, compensatory mechanisms are overwhelmed or incapacitated. Impaired functioning of various natural regulating pathways of coagulation activation may amplify further thrombin generation and contribute to fibrin formation.

Plasma levels of the most important inhibitor of thrombin, antithrombin, are usually markedly reduced in patients with DIC. This reduction is caused by the following:

Low antithrombin levels in DIC are associated with increased mortality, particularly in patients with sepsis.[19] That low levels of antithrombin precede the clinical manifestation of sepsis in prospective studies suggests that antithrombin is indeed involved in the pathogenesis of this disease and associated organ dysfunction.[25]

In addition to the decrease in antithrombin, significant depression of the protein C system may occur. Protein C, along with protein S, also serves as a major anticoagulant compensatory mechanism. Under normal conditions, protein C is activated by thrombin when complexed on the endothelial cell surface with thrombomodulin.[14] Activated protein C combats coagulation via proteolytic cleavage of factors Va and VIIIa and proteolyzes PAR1 when bound to the endothelial cell protein C receptor (EPCR).

Impaired functioning of the protein C pathway is mainly due to down-regulation of thrombomodulin expression or its inactivation by cellular reactive oxygen species on endothelial cells by proinflammatory cytokines such as tumor necrosis factor-alpha (TNF-α) and interleukin (IL)–1b.[26] This downregulation has been confirmed in studies in patients with meningococcal sepsis.

In combination with low levels of zymogen protein C (due to mechanisms similar to those described for antithrombin), this process results in diminished protein C activation, which will enhance the procoagulant state. Protein C levels are further reduced via consumption, extravascular leakage, renal loss, and reduced hepatic production and by a reduction in circulating free protein S. The availability of protein S to serve as a cofactor for activated protein C is regulated by the degree it is bound to the complement protein C4B-binding protein.

Animal experiments involving severe inflammation-induced coagulation activation convincingly show that compromising the protein C system results in increased morbidity and mortality, whereas restoring adequate functioning of activated protein C improves survival and organ failure. Experiments show that mice with a 1-allele targeted deletion of the protein C gene (resulting in heterozygous protein C deficiency) have more severe DIC and organ dysfunction and a higher mortality than wild-type littermates.

Besides being implicated in the physiologic regulation of thrombin formation, activated protein C probably also has important inflammation-modulating effects, which may be of relevance in the pathogenesis of DIC.

TF pathway inhibitor (TFPI) is another anticoagulant mechanism that is disabled in DIC. TFPI reversibly inhibits factor Xa and thrombin (indirectly) and has the ability to inhibit the TF-VIIa complex. Although levels of TFPI are normal in patients with sepsis, a relative insufficiency in DIC is evident. TFPI depletion in animal models predisposes to DIC, and TFPI blocks the procoagulant effect of endotoxin in humans.[27] The role of TFPI in the pathogenesis of DIC has not been fully clarified.

The experimental finding that administration of recombinant TFPI blocks inflammation-induced thrombin generation in humans, along with the observation that pharmacologic doses of TFPI are capable of preventing mortality during systemic infection and inflammation, suggests that high concentrations of TFPI are capable of modulating TF-mediated coagulation. Presumably, however, the endogenous concentration of TFPI is insufficiently capable of regulating coagulation activation and the downstream consequences during systemic inflammation.

Defective fibrinolysis

The intravascular fibrin produced by thrombin is normally eliminated via a process termed fibrinolysis. Experimental models indicate that at the time of maximal activation of coagulation, the fibrinolytic system is largely shut off.

Experimental bacteremia and endotoxemia result in a rapid increase in fibrinolytic activity, most probably caused by release of plasminogen activators from endothelial cells. However, this profibrinolytic response is almost immediately followed by suppression of fibrinolytic activity due to a sustained increase in plasma levels of PAI-1[28] ; these effects are mediated by TNF-2 and IL-1.[29] High PAI-1 levels precede DIC and predict poor outcomes.[30]

Notably, strategies that can block endotoxin-induced thrombin generation completely, such as anti-TF antibodies or recombinant hirudin (r-hirudin), have no significant effect on activation and subsequent inhibition of fibrinolysis, which suggests that these 2 processes are independently regulated.

In a study of 69 DIC patients (31 with multiorgan failure), higher levels of tissue plasminogen activator (t-PA) antigen and PAI-1 with depressed levels of α2 -antiplasmin were observed in patients with DIC and multiorgan failure than in DIC patients without multiorgan failure.[31] This finding supports the conclusion that fibrinolysis is a mechanism vital to the prevention of multiorgan failure.

Playing a key role in the process of coagulation and hemostasis is the vascular endothelium, which is responsible for the production of von Willebrand factor (vWF). vWF mediates the adhesion between the platelet surface receptors and the vessel wall and is increased in cases of thrombotic microangiopathy related to DIC. Impaired control of endothelial cell thrombomodulin expression may result in facilitated thrombin generation, which subsequently results in increased platelet activation and the conversion of fibrinogen to fibrin.[32]

Rare cases of DIC are characterized by a severe hyperfibrinolytic state on top of an activated coagulation system. Examples of such situations are the DIC that occurs as a complication of acute myeloid leukemia M-3 (in the French-American-British [FAB] classification) or the DIC that may occur secondary to some forms of adenocarcinoma. Although hyperfibrinolysis predominates in this situation, disseminated thrombosis is still found in a considerable number of patients at autopsy. Clinically, however, these patients suffer from severe bleeding.

In general, patients with DIC should not be treated with antifibrinolytic agents, because this may increase the fibrinolytic deficit and may result in increased thrombosis.

Inflammatory activation

Inflammatory and coagulation pathways interact in substantial ways. It is clear that there is cross-communication between the 2 systems, whereby inflammation gives rise to activation of the clotting cascade and the resultant coagulation stimulates more vigorous inflammatory activity. There are a number of different triggers that can cause a hemostatic imbalance, giving rise to a hypercoagulable state.

Many of the activated coagulation factors produced in DIC contribute to the propagation of inflammation by stimulating endothelial cell release of proinflammatory cytokines.[33] Factor Xa, thrombin, and the TF-VIIa complex have each been demonstrated to elicit proinflammatory action. Furthermore, given the anti-inflammatory action of activated protein C and antithrombin, depression of these anticoagulants in DIC contributes to further dysregulation of inflammation.[6, 34, 35]

Etiology

Several disease states may lead to the development of DIC (see Tables 1 and 2 below), generally via one of the following two pathways:

In some situations (eg, major trauma or severe necrotizing pancreatitis), both pathways may be present.

Table 1. Causes of Acute (Hemorrhagic) Disseminated Intravascular Coagulation



View Table

See Table

 

Table 2. Causes of Chronic Disseminated Intravascular Coagulation



View Table

See Table

Bacterial infection (in particular, bloodstream infection [BSI]) is commonly associated with DIC. There is no difference in the incidence of DIC between patients with gram-negative sepsis and those with gram-positive sepsis. Systemic infections with other microorganisms, such as viruses and parasites, may lead to DIC as well.

Factors involved in the development of DIC in patients with infections may be specific cell membrane components of the microorganism (lipopolysaccharide or endotoxin) or bacterial exotoxins (eg, staphylococcal alpha toxin). These components cause a generalized inflammatory response, characterized by the systemic occurrence of proinflammatory cytokines.

Severe trauma is another clinical condition frequently associated with DIC. A combination of mechanisms—including release of tissue material (eg, tissue factor [thromboplastin], fat or phospholipids) into the circulation, hemolysis, and endothelial damage—may contribute to systemic activation of coagulation. In addition, solid evidence indicates that cytokines also play a pivotal role in the occurrence of DIC in trauma patients. In fact, systemic cytokine patterns have been shown to be virtually identical in trauma patients and septic patients.

Both solid tumors and hematologic malignancies may be complicated by DIC. The mechanism by which coagulation is deranged in this situation is poorly understood. Solid tumor cells can express different procoagulant molecules, including TF and a cancer procoagulant. Cancer procoagulant is found in extracts of neoplastic cells and in the plasma of patients with solid tumors. As noted, some tumors are associated with a form of DIC that is characterized by severe hyperfibrinolysis on top of an activated coagulation system.

Acute DIC occurs in obstetric calamities such as placental abruption (abruptio placentae) and amniotic fluid emboli. Amniotic fluid has been shown to be able to activate coagulation in vitro, and the degree of placental separation correlates with the extent of the DIC, suggesting that leakage of thromboplastinlike material from the placental system is responsible for the occurrence of DIC.

Although the coagulation system may be activated in patients with preeclampsia and HELLP (hemolysis, elevated liver enzymes, and low platelet count) syndrome, clinically significant DIC occurs in only a small percentage of patients, usually in association with secondary complications.

Vascular disorders, such as large aortic aneurysms or giant hemangiomas (Kasabach-Merritt syndrome), may result in local activation of coagulation. Activated coagulation factors can ultimately “overflow” to the systemic circulation and cause DIC, but systemic depletion of coagulation factors and platelets as a result of local consumption is a more common scenario.

Epidemiology and Prognosis

DIC may occur in 30-50% of patients with sepsis,[37] and it develops in an estimated 1% of all hospitalized patients.[5] DIC occurs at all ages and in all races, and no particular sex predisposition has been noted.

The prognosis of patients with DIC depends on the severity of the coagulopathy and on the underlying condition that led to DIC. Assigning numerical figures to DIC-specific morbidity and mortality is difficult. The following are examples of mortality figures for diseases complicated by DIC:

A retrospective single-center Korean study of women with primary post-partum hemorrhage who presented to the emergency department found that 57 (22.4%) of the 255 patients had overt DIC. Of patients with DIC, 96.5% experienced major adverse events.

DIC criteria based on the Japanese Association for Acute Medicine DIC criteria with the addition of the hemostatic endothelial molecular markers  protein C activity and plasminogen activator inhibitor 1 had a sensitivity of 84.6% and a specificity of 80.3% for predicting mortality in a study of 79 patients with severe sepsis or septic shock. Using these criteria, DIC-positive patients also had significantly higher disease severity,[38]

In general, if the underlying condition is self-limited or can be appropriately handled, DIC will disappear, and the coagulation status will normalize. A patient with acute hemorrhagic DIC that is associated with metastatic gastric carcinoma likely has a lethal condition that does not alter patient demise, regardless of treatment. On the other hand, a patient with acute DIC associated with abruptio placentae needs quick recognition and obstetric treatment; the DIC will resolve with the treatment of the obstetric catastrophe.

Obviously, the clinical importance of a severe depletion of platelets and coagulation factors in patients with diffuse, widespread bleeding or in patients who need to undergo an invasive procedure is clear. In addition, the intravascular deposition of fibrin, as a result of the systemic activation of coagulation, contributes to organ failure and mortality.[39]

Histologic studies in patients with DIC show the presence of ischemia and necrosis due to fibrin deposition in small and medium-sized vessels of various organs. The presence of these intravascular thrombi appears to be clearly and specifically related to the clinical dysfunction of the organ. Specific thrombotic complications that are sometimes seen in the framework of DIC are acral cyanosis, hemorrhagic skin infarctions, and limb ischemia.

In addition, experimental animal studies of DIC show fibrin deposition in various organs. Amelioration of DIC by various interventions appears to improve organ failure and, in some but not all cases, mortality.

Finally, DIC has been shown to be an independent predictor of mortality in patients with sepsis and severe trauma.[40, 41, 42, 43] The presence of DIC may increase the risk of death by a factor of 1.5 to 2.0 in various studies. An increasing severity of DIC is directly related to an increased mortality.

A study utilizing the Japanese Association for Acute Medicine (JAAM) diagnostic criteria for DIC showed that septic patients with DIC had a higher mortality than trauma patients with DIC did (34.7% vs 10.5%).[44]

Complications

Complications of DIC include the following:

History

The symptoms of disseminated intravascular coagulation (DIC) are often those of the underlying inciting condition (see Etiology). Such conditions may include the following:

In addition to the symptoms related to the underlying disease process, there is typically a history of blood loss through bleeding in areas such the gingivae and the gastrointestinal (GI) system (see Table 3 below).[44] Acutely presenting DIC often manifests as petechiae and ecchymosis, along with blood loss from intravenous (IV) lines and catheters. In postoperative DIC, bleeding can occur in the vicinity of surgical sites, drains, and tracheostomies, as well as within serous cavities.

Table 3. Main Features of Disseminated Intravascular Coagulation in Series of 118 Patients



View Table

See Table

Look for symptoms and signs of thrombosis in large vessels (eg, deep vein thrombosis [DVT]) and microvascular thrombosis (as in renal failure). Bleeding from at least 3 unrelated sites is particularly suggestive of DIC. As many as 25% of patients present with renal failure. Patients with pulmonary involvement can present with dyspnea, hemoptysis, and cough. Comorbid liver disease as well as rapid hemolytic bilirubin production may lead to jaundice. Neurologic changes (eg, coma, obtunded mental status, and paresthesias) are also possible.

Physical Examination

With acute DIC, the physical findings are usually those of the underlying or inciting condition; however, patients with the acute disease (ie, the hemorrhagic variety associated with excess plasmin formation) have petechiae on the soft palate, trunk, and extremities from thrombocytopenia and ecchymosis at venipuncture sites. These patients also manifest ecchymosis in traumatized areas.

In patients with so-called chronic or subacute DIC, of which the primary manifestation is thrombosis from excess thrombin formation, the signs of venous thromboembolism may be present.

Circulatory signs include the following:

Central nervous system signs include the following:

Cardiovascular signs include the following:

Respiratory signs include the following:

Gastrointestinal signs include the following:

Genitourinary signs include the following:

Dermatologic signs include the following:

Approach Considerations

Diagnosis of disseminated intravascular coagulation (DIC) can be difficult, especially in cases of chronic, smoldering DIC, where clinical and laboratory abnormalities may be subtle.[47] No single routinely available laboratory test is sufficiently sensitive or specific to allow a diagnosis of DIC; however, several commonly available laboratory tests often yield abnormal results in DIC. Typically, moderate-to-severe thrombocytopenia is present. Furthermore, the peripheral blood smear can demonstrate evidence of microangiopathic pathology (schistocytes). Scoring systems have been developed to facilitate diagnosis of DIC.

Imaging studies are useful only to detect an underlying cause; the diagnosis of DIC is made by combining the clinical impression with any laboratory abnormalities noted.

No specific procedures help establish a specific diagnosis of DIC. However, a number of different procedures may help to diagnose the underlying causative condition.

Laboratory Studies

Patients with DIC can present with a wide range of abnormalities in their laboratory values. Typically, prolonged coagulation times, thrombocytopenia, high levels of fibrin degradation products (FDPs), elevated D-dimer levels, and microangiopathic pathology (schistocytes) on peripheral smears are suggestive findings.

Most individual laboratory tests demonstrate high sensitivity for DIC but very low specificity.[48] Furthermore, whereas acute DIC typically overwhelms compensatory anticoagulation mechanisms, resulting in depletion of factors and laboratory derangements, chronic or localized DIC may produce only minimal abnormalities in laboratory tests.[49]

It is essential to keep in mind that laboratory values may represent only a momentary glimpse into a very rapidly changing systemic process and that repeated tests may therefore be necessary in order to make a more clinically certain diagnosis.[4]

Standard tests

In clinical practice, a diagnosis of DIC can often be made by a combination of the following tests[37] :

Platelet count

Typically, moderate-to-severe thrombocytopenia is present in DIC. Thrombocytopenia is seen in as many as 98% of DIC patients, and the platelet count can dip below 50 × 109/L in 50%.[50] A trend toward decreasing platelet counts or a grossly reduced absolute platelet count is a sensitive (though not specific) indicator of DIC.[37] Repeated platelet counts are often necessary, as a single platelet measurement may indicate a level within the normal range, whereas trend values might show a precipitous drop from previous levels.

The peripheral blood smear can reveal schistocytes, though these are rarely seen to exceed 10% of red blood cells (RBCs). The presence of schistocytes is neither sensitive nor specific for DIC, but in certain instances, it may help confirm a chronic DIC diagnosis when the schistocytes are seen in concert with normal coagulation values and increased D-dimer levels.[50]

Clotting times and coagulation factors

Global clotting times (ie, activated partial thromboplastin time [aPTT] and prothrombin time [PT]) are typically prolonged. In as many as 50% of DIC patients, however, a normal or even an attenuated PT and aPTT may be encountered; consequently, such values cannot be used to exclude DIC.[51] This phenomenon may be attributed to certain activated clotting factors present in the circulation, such as thrombin or Xa, which may in fact enhance thrombin formation.[31]

It should be emphasized that serial coagulation tests are usually more helpful than single laboratory results in establishing the diagnosis of DIC. It is also important to note that the PT, not the international normalized ratio (INR), should be used in the DIC monitoring process; INR is recommended only for monitoring oral anticoagulant therapy.[37]

The prolongation of global clotting times may reflect the consumption and depletion of various coagulation factors, which may be further substantiated by the measurement of selected coagulation factors, such as factor V and factor VII. Measurement of coagulation factors may be helpful for detecting additional hemostatic abnormalities (eg, those caused by vitamin K deficiency).

Protein C and antithrombin are 2 natural anticoagulants that are frequently decreased in DIC. There is some evidence to suggest that they may serve roles as prognostic indicators.[52, 53] Nonetheless, the practical application of measuring these anticoagulants may be limited for most practitioners because the tests may not be generally available.[37]

DIC is associated with an unusual light transmission profile on the aPTT, known as a biphasic waveform. In one study, the degree of biphasic waveform abnormality had an increasing positive predictive value for DIC, independent of clotting time prolongation.[54] In addition, the waveform abnormalities are often evident before more conventionally used laboratory value derangements,[54] making this a quick and robust test for DIC. At present, however, the photo-optical analyzers necessary in clot formation analysis are not widely available.

Tests for fibrinogen, D-dimer, and FDPs

Because fibrin activation is a central component of DIC, it would seem logical to assume that if soluble fibrin is elevated, the diagnosis of DIC can be made with confidence.[55] However, soluble fibrin levels are not available to most clinicians within a relevant time frame. Likewise, laboratory assays aimed at differentiating between cross-linked fibrin, fibrinogen, and soluble fibrin have been developed but are not routinely available to the clinician.

The massive fibrin deposition in DIC suggests that fibrinogen levels would be decreased. Accordingly, measurement of fibrinogen has been widely advocated as a useful tool for the diagnosis of DIC; however, it is in fact not very helpful. Fibrinogen, as a positive acute-phase reactant, is increased in inflammation, and whereas values may decrease as the illness progresses, they are rarely low.[14, 56] One study demonstrated that in up to 57% of DIC patients, the levels of fibrinogen may in fact remain within normal limits.[50]

In a consecutive series of patients, the sensitivity of a low fibrinogen level for the diagnosis of DIC was only 28%, and hypofibrinogenemia was detected in a very small number of severe cases of DIC only. Sequential measurements of fibrinogen might be more useful and might be more likely to provide diagnostic clues.

Fibrinolysis is an important component of DIC; thus, there will be evidence of fibrin breakdown, such as elevated levels D-dimer and FDPs. D-dimer elevation means that thrombin has proteolyzed fibrinogen to form fibrin that has been cross-linked by thrombin-activated factor XIIIa. When fibrin becomes cross-linked insoluble, a unique D-D domain neoepitope forms. This cross-linked insoluble fibrin is then proteolyzed uniquely by plasmin to liberate the soluble D-D dimer. Thus, the D-dimer measures prior thrombin and plasmin formation. On the other hand, FDPs only inform that plasmin has been formed and it cleaved soluble fibrinogen, fibrin, or insoluble cross-linked fibrin. D-dimer is the better test for DIC.

Accordingly, testing for D-dimer or FDPs may be helpful for differentiating DIC from other conditions that may be associated with a low platelet count and prolonged clotting times, such as chronic liver disease. Most laboratories have an operational test for D-dimer. In the United States, FDPs are not used as often.

D-dimer or FDPs may be detected by means of specific enzyme-linked immunosorbent assay (ELISA) or latex agglutination assay, allowing rapid and bedside determination in emergency cases. However, some of the available assays for FDPs cross-react with fibrinogen degradation products, and this cross-reactivity may cause spuriously high results. The specificity of high levels of D-dimer and FDPs is therefore limited, and many other conditions (eg, venous thromboembolism, trauma, inflammation, and recent surgery) may be associated with elevated FDP levels.[14, 57]

Specialized tests

In a specialized setting, molecular markers for activation of coagulation or fibrin formation may be the most sensitive assays for DIC.[58] A number of clinical studies show that the presence of soluble fibrin in plasma has a 90-100% sensitivity for DIC but, unfortunately, a relatively low specificity. As noted (see above) a reliable test for quantifying soluble fibrin in plasma is not available, and one study showed a wide discordance among various assays.

The dynamics of DIC can also be judged by measuring activation markers that are released upon the conversion of the coagulation factor zymogen to an active protease, such as prothrombin activation fragment F1+2 (F1+2). Indeed, these markers are markedly elevated in patients with DIC, but again, the specificity is a problem.

In addition to the known limitations in specificity, many of the more sensitive and sophisticated tests described above are not available to general hematology laboratories. Although these tests may be very helpful in clinical trials or other research, they often cannot be used in a routine setting.

Evidence also suggests that serum levels of thrombomodulin, a marker for endothelial cell damage, correlate well with the clinical course of DIC, the development of multiple organ dysfunction syndrome (MODS), and mortality in septic patients. Thrombomodulin is elevated in DIC, and such elevation and not only correlates well with the severity of DIC but also can serve as a marker for early identification and monitoring of DIC.[59]

Regardless of the discussion above, most hospitals of all sizes in the developed world have available PT, aPTT, fibrinogen, platelet count, and D-dimer. These tests alone are sufficient to make or exclude a clinical diagnosis of DIC in the practice of medicine.

DIC Scoring Systems

The diagnosis of DIC relies on multiple clinical and laboratory determinations. The International Society on Thrombosis and Haemostasis (ISTH) developed a simple scoring system for the diagnosis of overt DIC that makes use of laboratory tests available in almost all hospital laboratories (see the image below, and the DIC Score calculator.)[4] The presence of an underlying disorder known to be associated with DIC (see Etiology) is a sine qua non for the use of this diagnostic algorithm.



View Image

Diagnostic algorithm for the diagnosis of overt disseminated intravascular coagulation.

A score of 5 or higher indicates overt DIC, whereas a score of less than 5 does not rule out DIC but may indicate DIC that is not overt.[4] Prospective validation studies show this scoring system to be highly accurate for the diagnosis of DIC. The sensitivity of the DIC score for a diagnosis of DIC is 91-93%, and the specificity is 97-98%.[58, 60]

Other analyses show that the DIC scoring system is a strong independent predictor of a fatal outcome in intensive care unit (ICU) patients. In these studies, mortality was higher than 40% in patients with sepsis and DIC (according to the scoring system), compared with about 25% in patients without DIC. For each DIC point in the system, the odds ratio for mortality is 1.29, whereas for each Acute Physiology and Chronic Health Evaluation (APACHE) classification system point, the odds ratio for mortality is 1.07.

Despite the demonstrable utility of the ISTH scoring system for diagnosing overt DIC, concerns have been expressed about its validity for identifying nonovert DIC. In response to these concerns, the Japanese Association for Acute Medicine (JAAM) developed a diagnostic algorithm and scoring system designed for use in critically ill patients (see Table 4 below).[61]

Table 4. Japanese Association for Acute Medicine (JAAM) Scoring System for DIC



View Table

See Table

This system has been prospectively validated and has been found to be capable of diagnosing DIC earlier than previous methods could. Furthermore, evidence suggests that early identification of DIC using this scoring system, as well as early and aggressive treatment of DIC and the underlying disorder, can lead to improvements in patient outcome and reductions in mortality.[61]

In a study of the JAAM DIC criteria in 79 patients with severe sepsis or septic shock, Umemura et al reported that the addition of two hemostatic endothelial molecular markers—protein C activity and plasminogen activator inhibitor 1—measured within 12 hours of admission, provided greater prognostic value, predicting mortality with a sensitivity of 84.6% and a specificity of 80.3%. Protein C activity correlated best with mortality, followed by plasminogen activator inhibitor 1. Using those criteria, DIC-positive patients also had significantly higher disease severity.[38]

Histologic Findings

Grossly, hemorrhage into all tissues (eg, brain, adrenal, lung, kidney) can develop in acute hemorrhagic DIC.

Histologic studies in patients with DIC show the presence of ischemia and necrosis due to fibrin deposition in small and medium-sized vessels of various organs. The presence of these intravascular thrombi appears to be clearly and specifically related to the clinical dysfunction of the organ. Specific thrombotic complications that are sometimes seen in the framework of DIC are acral cyanosis, hemorrhagic skin infarctions, and limb ischemia.

Approach Considerations

Treatment of disseminated intravascular coagulation (DIC) is controversial, but treatment guidelines have been published and offer broadly similar recommendations.[37, 62, 63] Treatment should primarily focus on addressing the underlying disorder. DIC can result from numerous clinical conditions, including sepsis, trauma, obstetric emergencies, and malignancy. Surgical management is limited to primary treatment of certain underlying disorders.

Management of the DIC itself has the following basic features:

Platelet and factor replacement should be directed not at simply correcting laboratory abnormalities but at addressing clinically relevant bleeding or meeting procedural needs. Heparin should be provided to those patients who demonstrate extensive fibrin deposition without evidence of substantial hemorrhage; it is usually reserved for cases of chronic DIC. Heparin is appropriate to treat the thrombosis that occurs with DIC. It also has a limited use in acute hemorrhagic DIC in a patient with a self-limited condition of acral cyanosis and digital ischemia.

Administration of activated protein C (drotrecogin alfa) showed benefit in subgroups of patients with sepsis who have DIC, with consideration given to the anticoagulant effects of this agent. However, drotrecogin alfa was withdrawn from the worldwide market on October 25, 2011, after the PROWESS-SHOCK trial failed to show a survival benefit for patients with severe sepsis and septic shock.[64]

Patients with DIC should be treated at hospitals with appropriate critical care and subspecialty expertise, such as hematology, blood bank, or surgery. Patients who present to hospitals without those capabilities and who are stable enough for transfer should be referred expeditiously to a hospital that has those resources.

Management of Underlying Disease

The management of acute and chronic forms of disseminated intravascular coagulation (DIC) should primarily be directed at treatment of the underlying disorder.[65] Often, the DIC component will resolve on its own once the underlying disorder is addressed.

For example, if infection is the underlying etiology, the appropriate administration of antibiotics and source control is the first line of therapy. As another example, in case of an obstetric catastrophe, the primary approach is to deliver appropriate obstetric care, in which case the DIC will rapidly subside. If the underlying condition causing DIC is not known, a diagnostic workup should be initiated. Most patients with acute DIC require critical care treatment appropriate for the primary diagnosis, occasionally including emergency surgery.

A DIC scoring system has been proposed by Bick to assess the severity of the coagulopathy as well as the effectiveness of therapeutic modalities.[2] Clinical and laboratory parameters are measured with regularity (every 8 hours).

Administration of Blood Components and Coagulation Factors

Typically, DIC results in significant reductions in platelet count and increases in coagulation times (prothrombin time [PT] and activated partial thromboplastin time [aPTT]). However, platelet and coagulation factor replacement should not be instituted on the basis of laboratory results alone; such therapy is indicated only in patients with active bleeding and in those requiring an invasive procedure or who are otherwise at risk for bleeding complications.

Platelets

Platelet transfusion may be considered in patients with DIC and severe thrombocytopenia, in particular, in patients with bleeding or in patients at risk for bleeding (eg, in the early postoperative phase or if an invasive procedure is planned).

The threshold for transfusing platelets varies. Most clinicians provide platelet replacement in nonbleeding patients if platelet counts drop below 20 × 109/L, though the exact levels at which platelets should be transfused is a clinical decision based on each patient’s clinical condition. In some instances, platelet transfusion is necessary at higher platelet counts, particularly if indicated by clinical and laboratory findings.[66] In actively bleeding patients, platelet levels from 20 × 109/L to 50 × 109/L are grounds for platelet transfusion (1 or 2 U/kg/day).

Coagulation factors

Previously, concerns have been expressed regarding the possibility that coagulation factor replacement therapy might “add fuel to the fire” of consumption; however, this has never been established in research studies.[67]

It is generally considered that cryoprecipitate and coagulation factor concentrates should not routinely be used as replacement therapy in DIC, because they lack several specific factors (eg, factor V). Additionally, worsening of the coagulopathy via the presence of small amounts of activated factors is a theoretical risk. Specific deficiencies in coagulation factors, such as fibrinogen, can be corrected by administration of cryoprecipitate or purified fibrinogen concentrate in conjuction with fresh frozen plasma (FFP) administration.

Data suggest that the consumption-induced deficiency of coagulation factors can be partially rectified by administering large quantities of FFP, particularly in patients with an international normalized ratio (INR) higher than 2.0, a 2-fold or greater prolongation of the aPTT, or a fibrinogen level below 100 mg/dL.[68] The suggested starting dose is 15 mg/kg.[37]

Repeated measurement of global clotting tests (eg, aPTT and PT) might be useful for monitoring the coagulation defect. In case of a (relative) vitamin K deficiency in the face of consumption, administration of vitamin K may be required.[14, 6, 15]

Anticoagulation

Experimental studies have suggested that heparin can at least partly inhibit the activation of coagulation in cases of sepsis and other causes of DIC.[69] However, a beneficial effect of heparin on clinically important outcome events in patients with DIC has not yet been demonstrated in controlled clinical trials. Moreover, antithrombin, the primary target of heparin activity, is markedly decreased in DIC, which means that the effectiveness of heparin therapy will be limited without concomitant replacement of antithrombin.

Furthermore, there are well-founded concerns with respect to anticoagulating DIC patients who are already at high risk for hemorrhagic complications. It is generally agreed that therapeutic doses of heparin are indicated in cases of obvious thromboembolic disease or where fibrin deposition predominates (eg, purpura fulminans or acral ischemia).[70, 71, 72] The use of heparin in chronic DIC where there is preponderance of coagulation without consumption coagulopathy is well established.[73] In other patients with acryl cyanosis and digital ischemia and DIC, heparin can be safely administered at lower doses. A dose of 4-5 U/kg constant infusion without a 80-U/kg bolus is a safe means to deliver heparin to the DIC without increasing the bleeding risk.

The use of low-molecular-weight heparin (LMWH) has been studied in DIC. Enoxaparin has been used for treatment and prophylaxis of chronic DIC in specific clinical situations. In a multicenter, cooperative, double-blinded trial from Japan that compared dalteparin with unfractionated heparin, the former was associated with a decreased bleeding tendency and reduced organ failure.[71] One randomized clinical trial showed LMWH to be superior for reducing 28-day mortality in patients with severe sepsis.[74]

Patients with DIC may benefit from prophylaxis to prevent venous thromboembolism, which will not be achieved with standard low-dose subcutaneous heparin. Theoretically, the most logical anticoagulant agent to use in DIC is directed against tissue factor activity.

Restoration of Anticoagulant Pathways

Strategies for restoring anticoagulant pathways have primarily involved administration of antithrombin concentrate or recombinant human APC (drotrecogin alfa); however, drotrecogin alfa was withdrawn from the worldwide market on October 25, 2011. Tissue factor (TF) pathway inhibitor (TFPI) and recombinant thrombomodulin (rTM) have also been studied.

Antithrombin

The antithrombin pathway, an important inhibitor of coagulation in normal patients, is largely depleted and incapacitated in acute DIC. As a result, several studies have evaluated the utility of antithrombin replacement in DIC. Most have demonstrated benefit in terms of improving laboratory values and even organ function.[56, 75, 76, 77] To date, however, large-scale randomized trials have failed to demonstrate any mortality benefit in patients treated with antithrombin concentrate.

Most of the randomized controlled trials involved patients with sepsis or septic shock. In the later clinical trials, very high doses of antithrombin concentrate were used to attain supraphysiologic plasma levels. A series of relatively small trials showed a modest reduction in mortality in antithrombin-treated patients. However, in none of the trials did the effect reach statistical significance.

A large-scale multicenter, randomized controlled trial to directly address this issue showed no significant reduction in mortality of septic patients who were treated with antithrombin concentrate. In this trial, 2114 patients with severe sepsis and associated organ failure were included. Surprisingly, subgroup analyses indicated some benefit in patients who did not receive concomitant heparin, but this observation needs prospective validation.

In another study that evaluated the effects of antithrombin in 23 patients with DIC diagnosed on the basis of the Japanese Association for Acute Medicine (JAAM) criteria (a newly developed diagnostic algorithm for critical illness), patients were treated with either high-dose (60 IU/kg/day; 12 patients) or low-dose (30 IU/kg/day; 11 patients) antithrombin concentrates for 3 days.[78]

On day 0, the patients’ backgrounds and antithrombin activity were identical in the 2 groups.[78] However, on day 7, the JAAM DIC score and PT ratio were significantly improved in comparison with those on day 0. However, mortality at 28 days and interaction within the administered antithrombin doses showed no differences.[78]

There were also no differences in the time course of the platelet counts, coagulation and fibrinolytic markers, and DIC scores in the 2 groups.[78] The authors concluded that the effects of antithrombin on prognosis and coagulation and fibrinolytic parameters are independent of the doses administered in patients who have DIC associated with the systemic inflammatory response syndrome (SIRS) or sepsis.

A retrospective Japanese study in 1784 patients with severe sepsis and DIC, 715 of whom received treatment with antithrombin, found a statistically significant association between antithrombin supplementation and lower in-hospital all-cause mortality (odds ratio 0.748, P = 0.034). However, that association was not evident on quintile-stratified propensity score analysis or propensity score matching analysis.[79]

In this study, similar results were observed in DIC patients with or without concomitant heparin administration. In addition, although the number of transfusions needed was higher in the group that received antithrombin, the number of severe bleeding complications was not.[79]

A recombinant form of antithrombin, antithrombin gamma, is being developed as an alternative to antithrombin derived from human plasma. In a randomized, open-label trial in 222 patients with sepsis-induced DIC, the safety and efficacy of antithrombin gamma were comparable to that of plasms-derived antithrombin.[80]

Tissue factor pathway inhibitor

The TFPI mechanism of coagulation inhibition has received attention as a potential therapy in sepsis-associated DIC. Indeed, initial results from animal studies have been very promising in demonstrating the ability of TFPI to arrest DIC and to prevent the mortality and end-organ damage witnessed in untreated animals.[81] However, a large phase III trial of TFPI in humans with DIC did not show any mortality benefit.[82]

Recombinant thrombomodulin

In Japan, rTM is widely used for treatment of DIC. Thrombomodulin binds with thrombin, and the resulting complex allows the conversion of protein C to APC. Additionally, thrombomodulin can also bind high-mobility group B (HBGM-1), which inhibits the inflammatory process.[68]

rTM has shown beneficial effects on DIC parameters and clinical outcome in initial trials.[83] It was evaluated in a randomized controlled study involving 234 subjects and was found to yield significantly improved control of DIC in comparison with unfractionated heparin, particularly with respect to the control of persistent bleeding diathesis.[84]

However, a meta-analysis by Zhang et al found that in patients with infection complicated by DIC, treatment with rTM does not decrease short-term mortality: the risk ratio for 28- or 30-day mortality was 0.81 in randomized controlled trials and 0.96 in observational studies.[85]  In a systematic review and meta-analysis by Yamakawa et al of rTM for sepsis-induced DIC, pooled relative risk of 28-30 day mortality was 0.81 (95% CI, 0.62–1.06) in randomized controlled trials, indicating a non‐significant reduction in mortality, and 0.59 (95% CI, 0.45–0.77) in observational studies; results suggested that the probability of rTM therapy having a beneficial effect increases with increasing baseline risk.[86]

Inoue et al reported benefit with rTM treatment of DIC caused by noninfectious complications of allogeneic hematopoietic stem cell transplantation, such as acute graft-versus-host disease or thrombotic microangiopathy. In 12 episodes of DIC in 10 patients, the recovery rate was significantly higher than in historical controls.[87]

Investigational Treatments

Recognition of the importance of inflammation in sepsis, coagulation, and DIC is vitally important in directing the development of novel therapeutic strategies. As understanding of the inflammatory and coagulation derangements in DIC has improved, the range of therapeutic considerations has broadened.

Treatment modalities focused on the tissue factor (TF)-VIIa complex include inactivated factor VII and recombinant nematode anticoagulant peptide (NAPc2), a member of the nematode family of anticoagulant proteins (NAPs) and an inhibitor of the complex between TF, factor VIIa, and factor Xa. NAPc2 has been observed to inhibit coagulation activation in a primate model of sepsis.[6, 15] Other research has used antibodies against TF-VIIa in animal trials, with promising results.[15]

Recombinant factor VIIa (rVIIa) has also been demonstrated to be useful in cases of severe bleeding, as is seen in DIC.[15] However, given the procoagulant effect of rVIIa, the risks and benefits of its use in patients with DIC should be carefully considered before administration.

Antifibrinolytic agents, such as ε-aminocaproic acid or tranexamic acid, can also be considered in patients with DIC in which bleeding predominates. These agents should always be administered with heparin to arrest their prothrombotic effects.[15, 88]

Recognition of the importance of inflammation in both sepsis and DIC has led to further investigation of inhibitors of inflammation. In a murine model, researchers showed that antiselectin antibodies and heparin blocked leukocyte and platelet adhesion.[89] Similarly, focus has been placed on interleukin (IL)–10, an anti-inflammatory cytokine that may have effects on coagulation activation. Initial studies of IL-10 have shown promise in preventing coagulation activation associated with endotoxemia.[90]

Other researchers have targeted p38 mitogen activated protein kinase (MAPK), an important element in intracellular signaling responsible for inflammatory responses. Inhibition of MAPK has been shown to reduce coagulation activation, fibrinolysis, and endothelial activation in endotoxemia.[91]

Activated protein C is an important regulator of coagulation. It deactivates factor VIIIa and factor Va and also has a role in activating protease-activated receptor 1 (PAR-1), which has an inhibitory effect on inflammation and apoptosis.[68] A study found protein C concentrate to be safe and useful in restoring coagulation and hematologic parameters in adult patients with sepsis; however, further study is required, and prospective evaluation of its safety and efficacy are indicated.[92]

Consultations

Consult a hematologist for assistance with diagnosis and management if the clinical picture is suggestive of DIC. Consult a transfusion specialist or a blood bank; determine the availability of general and specialized blood products that may be necessary for the acute management of fulminant DIC. Consult a critical care specialist if multiple organ failure is present.

Early consultation is indicated for this complicated, life-threatening condition. Obtain other subspecialty consultations as indicated by the patient’s primary diagnosis.

Long-Term Monitoring

Outpatient medications may include antiplatelet agents for those with low-grade DIC, antibiotics appropriate to the primary diagnosis, or both. Patients who recover from acute DIC should follow up with their primary care provider or a hematologist. Patients with low-grade or chronic DIC may be treated by a hematologist on an outpatient basis after initial assessment and stabilization. Chronic DIC in patients with cancer can be managed with subcutaneous heparin or low molecular weight heparin.

Medication Summary

The goals of pharmacotherapy in cases of disseminated intravascular coagulation (DIC) are to reduce morbidity and to prevent complications. Therapy should be based on etiology and aimed at eliminating the underlying disease. Treatment should be appropriately aggressive for the patient’s age, disease, and severity and location of hemorrhage or thrombosis. Treatment of acute DIC includes anticoagulants, blood components, and antifibrinolytics. Hemostatic and coagulation parameters should be monitored continuously during treatment.

Base therapeutic decisions on clinical and laboratory evaluation of hemostasis. In cases of low-grade DIC, therapy other than supportive care may not be warranted or may include antiplatelet agents or subcutaneous heparin; treatment decisions should be based on clinical and laboratory evaluation of hemostasis.

Heparin

Clinical Context:  Heparin augments the activity of antithrombin and prevents conversion of fibrinogen to fibrin. It does not actively lyse but is able to inhibit further thrombogenesis. It prevents reaccumulation of clot after spontaneous fibrinolysis. Usage and dosing of heparin are based on the severity of DIC, the underlying cause, and the extent of thrombosis. Monitoring the results of therapy is mandatory.

Antithrombin (Atryn, Thrombate III)

Clinical Context:  Antithrombin is used for moderately severe–to–severe DIC or when levels are depressed markedly. It is an alpha2-globulin that inactivates thrombin, plasmin, and other serine proteases of coagulation, including factors IXa, Xa, XIa, XIIa, and VIIa. These effects inhibit coagulation.

Class Summary

Anticoagulants are used in the treatment of clinically evident intravascular thrombosis when the patient continues to bleed or clot 4-6 hours after initiation of primary and supportive therapy. Thrombosis can present as purpura fulminans or acral ischemia. Take special precaution in obstetric emergencies or massive liver failure. The anti-inflammatory properties of antithrombin may be particularly useful in DIC secondary to sepsis.

Heparin is the only currently available antithrombotic drug that has a role in the treatment of patients with DIC. Although most experience is with standard heparin, low-molecular-weight heparins (LMWHs) are increasingly used. Moreover, although LMWHs usually do not require laboratory monitoring, it may be advisable to check anti-factor Xa levels in critically ill patients with serious renal failure.

Drotecogin alfa (Xigris)

Clinical Context:  Withdrawn from the worldwide market on October 25, 2011. Drotrecogin alfa was approved for the reduction of mortality in patients who have severe sepsis associated with acute organ dysfunction and who are at high risk for death. It is a recombinant form of human APC that exerts an antithrombotic effect by inhibiting factors Va and VIIIa.

Drotrecogin alfa exercises indirect profibrinolytic activity by inhibiting PAI-1 and limiting formation of activated thrombin-activatable fibrinolysis inhibitor. It may exert an anti-inflammatory effect by inhibiting human tumor necrosis factor (TNF) production by monocytes, blocking leukocyte adhesion to selectins, and limiting thrombin-induced inflammatory responses within the microvascular endothelium.

Class Summary

Recombinant human APC inhibits factors Va and VIIIa of the coagulation cascade. It may also inhibit plasminogen activator inhibitor-1 (PAI-1). Drotrecogin alfa (Xigris) was withdrawn from the worldwide market on October 25, 2011.

Packed red blood cells (PRBCs; washed)

Clinical Context:  PRBCs are preferred to whole blood because they limit volume, immune, and storage complications. Obtain PRBCs after centrifugation of whole blood. Use washed or frozen PRBCs in individuals with hypersensitivity transfusion reactions.

Platelets

Clinical Context:  Platelets are considered safe for use in acute DIC.

Fresh frozen plasma (FFP)

Clinical Context:  FFP treatment entails removing blood from the body, spinning it to separate cells from plasma, and replacing cells suspended in fresh frozen plasma, albumin, or saline. FFP contains coagulation factors, as well as protein C and protein S. It can be administered either via 2 large-bore peripheral intravenous lines or via 1 multiple-lumen central line. It is recommended for patients with active bleeding and a fibrinogen level below 100 mg/dL.

Cryoprecipitate or fibrinogen concentrates

Clinical Context:  Cryoprecipitate and fibrinogen concentrates are not commonly recommended, except when fibrinogen is needed.

Class Summary

Blood components are used to correct abnormal hemostatic parameters. These products should be considered only after initial supportive and anticoagulant therapy. Washed packed red blood cells (PRBCs) and platelet concentrates are considered safe in uncontrolled DIC. Specialized blood components (eg, cryoprecipitate and fresh frozen plasma [FFP]) may interfere with or alleviate DIC.

Aminocaproic acid (Amicar)

Clinical Context:  Aminocaproic acid inhibits fibrinolysis by inhibiting plasminogen activators and, to a lesser degree, exerting antiplasmin activity. The main problem is that the thrombi that form during treatment are not lysed and that the clinical significance of reducing bleeding is uncertain.

Tranexamic acid (Cyklokapron, Lysteda)

Clinical Context:  Tranexamic acid is used as an alternative to aminocaproic acid. It inhibits fibrinolysis by displacing plasminogen from fibrin.

Class Summary

In general, antifibrinolytic agents should be avoided in DIC because they are known to produce thrombotic complications, such as myocardial infarction and renal artery thrombosis when there is systemic clotting. They may have a role in a local intravascular coagulation (LIC) as is seen in genitourinary bleeding after a transurethral resection for Kasabach-Merritt syndrome.

In addition, in patients with trauma and massive bllood loss, antifibrinolytic agents have been shown to be effective in reducing blood loss and improving survival.[93] Similarly, in massive postpartum hemorrhage, antifibrinolytic agents have been shown to be effective.[94] Antifibrinolytics also may be useful in cases of DIC secondary to hyperfibrinolysis associated with acute promyelocytic leukemia and other forms of cancer when alpha-2-antiplasmin is uniquely decreased.

How is disseminated intravascular coagulation (DIC) characterized?What is the ISTH definition of disseminated intravascular coagulation (DIC)?What is the prevalence of disseminated intravascular coagulation (DIC) and which conditions may be complicated by DIC?What causes disseminated intravascular coagulation (DIC)?What are the symptoms of disseminated intravascular coagulation (DIC)?How do acute and chronic disseminated intravascular coagulation (DIC) develop?What is the pathogenesis of hematologic derangements in disseminated intravascular coagulation (DIC)?When is thrombin generation detectable in the pathophysiology of disseminated intravascular coagulation (DIC)?What is the role of tissue factor (TF) in the pathogenesis of disseminated intravascular coagulation (DIC)?What is the role of thrombin in the pathophysiology of disseminated intravascular coagulation (DIC)?What is the role of factor VIIa in the pathogenesis of disseminated intravascular coagulation (DIC)?What prevents the pathogenesis of disseminated intravascular coagulation (DIC)?What is the source of tissue factor (TF) in the pathogenesis of disseminated intravascular coagulation (DIC)?How is thrombin generation regulation disrupted in the pathophysiology of disseminated intravascular coagulation (DIC)?What reduces plasma levels of antithrombin in disseminated intravascular coagulation (DIC)?What is the role of antithrombin in the pathophysiology of disseminated intravascular coagulation (DIC)?What is the role of the protein C system in the pathophysiology of disseminated intravascular coagulation (DIC)?What is the role of TF pathway inhibitor (TFPI) in the pathophysiology of disseminated intravascular coagulation (DIC)?What is the role of the fibrinolytic system in the pathophysiology of disseminated intravascular coagulation (DIC)?What suppresses fibrinolytic activity in the pathogenesis of disseminated intravascular coagulation (DIC)?What effect do anti-TF antibodies or recombinant hirudin have on the inhibition of fibrinolysis in disseminated intravascular coagulation (DIC)?What finding supports fibrinolysis as a preventive factor of multiorgan failure in disseminated intravascular coagulation (DIC)?What is the role of von Willebrand factor (vWF) in the pathogenesis of disseminated intravascular coagulation (DIC)?How are rare cases of disseminated intravascular coagulation (DIC) characterized?What treatment is contraindicated in patients with disseminated intravascular coagulation (DIC)?How do inflammatory and coagulation pathways interact in the pathophysiology of disseminated intravascular coagulation (DIC)?What is the role of activated coagulation factors in the inflammatory process of disseminated intravascular coagulation (DIC)?What are the disease pathways that lead to the development of disseminated intravascular coagulation (DIC)?Which pathogens are associated with disseminated intravascular coagulation (DIC)?Which factors increase the risk of developing disseminated intravascular coagulation (DIC) in patients with infections?What is the role of trauma in the development of disseminated intravascular coagulation (DIC)?Which conditions may be complicated by disseminated intravascular coagulation (DIC)?How does acute disseminated intravascular coagulation (DIC) occur as a complication of pregnancy?When is clinically significant disseminated intravascular coagulation (DIC) likely to occur?How do vascular disorders lead to disseminated intravascular coagulation (DIC)?How is the Japanese Association for Acute Medicine (JAAM) diagnostic criteria used to predict mortality in disseminated intravascular coagulation (DIC)?What are complications of disseminated intravascular coagulation (DIC)?What is the prevalence of disseminated intravascular coagulation (DIC)?What is the prognosis and mortality rate of disseminated intravascular coagulation (DIC)?What is the prognosis of disseminated intravascular coagulation (DIC)?What do histologic studies in patients with disseminated intravascular coagulation (DIC) reveal?What has been reported in experimental animal studies of disseminated intravascular coagulation (DIC)?How much does disseminated intravascular coagulation (DIC) increase mortality in patients with sepsis and severe trauma?What are the signs and symptoms of disseminated intravascular coagulation (DIC)?What history suggests disseminated intravascular coagulation (DIC) and how does acutely presenting DIC manifest?What is the presentation of disseminated intravascular coagulation (DIC)?Which physical findings suggest disseminated intravascular coagulation (DIC) and what is the presentation of chronic or subacute DIC?What are the hematologic signs of disseminated intravascular coagulation (DIC)?What are the central nervous system signs of disseminated intravascular coagulation (DIC)?What are the cardiovascular signs of disseminated intravascular coagulation (DIC)?What are the respiratory signs of disseminated intravascular coagulation (DIC)?What are the GI signs of disseminated intravascular coagulation (DIC)?What are the genitourinary signs of disseminated intravascular coagulation (DIC)?What are the dermatologic signs of disseminated intravascular coagulation (DIC)?Which conditions should be included in the differential diagnosis of disseminated intravascular coagulation (DIC)?How is thrombotic thrombocytopenic purpura (TTP)-hemolytic uremic syndrome (HUS) differentiated from disseminated intravascular coagulation (DIC)?How is immune thrombocytopenic purpura (ITP) differentiated from disseminated intravascular coagulation (DIC)?How is heparin-induced thrombocytopenia and thrombosis syndrome (HITTS) differentiated from disseminated intravascular coagulation (DIC)?What are the differential diagnoses for Disseminated Intravascular Coagulation?How is disseminated intravascular coagulation (DIC) diagnosed?Which lab test findings suggest disseminated intravascular coagulation (DIC)?What are the limitations of lab testing in the workup of disseminated intravascular coagulation (DIC)?Which lab tests are performed in the workup of disseminated intravascular coagulation (DIC)?What is the role of platelet count in the workup of disseminated intravascular coagulation (DIC)?What is the role of global clotting times and coagulation factors in the workup of disseminated intravascular coagulation (DIC)?What is the role of soluble fibrinogen measurement in the workup of disseminated intravascular coagulation (DIC)?What is the role of D-dimer and fibrin degradation product (FDP) tests in the workup of disseminated intravascular coagulation (DIC)?What are the most sensitive assays for the diagnosis of disseminated intravascular coagulation (DIC)?What is the role of activation markers in the workup of disseminated intravascular coagulation (DIC)?What are the limitations in availability of diagnostic tests for disseminated intravascular coagulation (DIC)?What is the role of thrombomodulin testing in the workup of disseminated intravascular coagulation (DIC)?What is the ISTH scoring system for the diagnosis of overt disseminated intravascular coagulation (DIC)?How is the ISTH scoring system used to predict mortality rates in disseminated intravascular coagulation (DIC)?What is the Japanese Association for Acute Medicine (JAAM) diagnostic algorithm and scoring system for disseminated intravascular coagulation (DIC)?How has the Japanese Association for Acute Medicine (JAAM) diagnostic algorithm and scoring system for disseminated intravascular coagulation (DIC) been validated?Which histologic findings support a diagnosis of disseminated intravascular coagulation (DIC)?What should be the focus of treatment of disseminated intravascular coagulation (DIC)?What are the features of disseminated intravascular coagulation (DIC) management?What is the role of heparin in the treatment of disseminated intravascular coagulation (DIC)?What is the role of activated protein C (drotrecogin alfa) for the treatment of disseminated intravascular coagulation (DIC)?What is the inpatient treatment for disseminated intravascular coagulation (DIC)?How is the appropriate therapy selected for the treatment of disseminated intravascular coagulation (DIC)?How is the severity of the coagulopathy and the effectiveness of treatment assessed in disseminated intravascular coagulation (DIC)?When is platelet and coagulation factor replacement therapy indicated in the treatment of disseminated intravascular coagulation (DIC)?When is platelet transfusion indicated in the treatment of disseminated intravascular coagulation (DIC)?What is the threshold for platelet transfusion in the treatment of disseminated intravascular coagulation (DIC)?What are the risks of coagulation factor replacement therapy for the treatment of disseminated intravascular coagulation (DIC)?How is consumption-induced deficiency of coagulation factors corrected in the treatment of disseminated intravascular coagulation (DIC)?Which tests are useful for monitoring the coagulation defect in disseminated intravascular coagulation (DIC) treatment?What are the risks of heparin anticoagulation therapy for the treatment of disseminated intravascular coagulation (DIC)?What is the role of low-molecular-weight heparin (LMWH) in the treatment of disseminated intravascular coagulation (DIC)?What is the role of anticoagulation prophylaxis in the treatment of disseminated intravascular coagulation (DIC)?What are the options for restoring anticoagulant pathways in the treatment of disseminated intravascular coagulation (DIC)?What is the role of antithrombin replacement in the treatment of disseminated intravascular coagulation (DIC)?What is the role of tissue factor pathway inhibitor (TFPI) in the treatment of disseminated intravascular coagulation (DIC)?What is the role of recombinant thrombomodulin (rTM) in the treatment of disseminated intravascular coagulation (DIC)?What is the focus of novel therapeutic strategies for disseminated intravascular coagulation (DIC)?Which treatments for disseminated intravascular coagulation (DIC) are focused on the tissue factor (TF)-VIIa complex?What is the role of recombinant factor VIIa (rVIIa) in the treatment of disseminated intravascular coagulation (DIC)?What is the role of antifibrinolytic agents in the treatment of disseminated intravascular coagulation (DIC)?What is the role of anti-inflammatory agents in the treatment of disseminated intravascular coagulation (DIC)?What is the role of activated protein C concentrate in the treatment of disseminated intravascular coagulation (DIC)?Which specialists should be consulted in the diagnosis and management of disseminated intravascular coagulation (DIC)?What long-term monitoring is needed following treatment of disseminated intravascular coagulation (DIC)?What are the goals of drug treatment in the management of disseminated intravascular coagulation (DIC)?What is the basis for therapeutic decisions in the treatment of disseminated intravascular coagulation (DIC)?Which medications in the drug class Antifibrinolytic Agents are used in the treatment of Disseminated Intravascular Coagulation?Which medications in the drug class Blood Components are used in the treatment of Disseminated Intravascular Coagulation?Which medications in the drug class Recombinant Human Activated Protein C are used in the treatment of Disseminated Intravascular Coagulation?Which medications in the drug class Anticoagulants, Hematologic are used in the treatment of Disseminated Intravascular Coagulation?

Author

Marcel M Levi, MD, Dean, Academic Medical Center, University of Amsterdam, The Netherlands

Disclosure: Nothing to disclose.

Coauthor(s)

Alvin H Schmaier, MD, Robert W Kellermeyer Professor of Hematology/Oncology, Case Western Reserve University School of Medicine; Chief, Division of Hematology/Oncology, University Hospitals Case Medical Center

Disclosure: Nothing to disclose.

Chief Editor

Srikanth Nagalla, MBBS, MS, FACP, Associate Professor of Medicine, Division of Hematology and Oncology, UT Southwestern Medical Center

Disclosure: Serve(d) as a director, officer, partner, employee, advisor, consultant or trustee for: Alexion; Alnylam.

Acknowledgements

Jeffrey L Arnold, MD, FACEP Chairman, Department of Emergency Medicine, Santa Clara Valley Medical Center

Jeffrey L Arnold, MD, FACEP is a member of the following medical societies: American Academy of Emergency Medicine and American College of Physicians

Disclosure: Nothing to disclose.

Joseph U Becker, MD Fellow, Global Health and International Emergency Medicine, Stanford University School of Medicine

Joseph U Becker, MD is a member of the following medical societies: American College of Emergency Physicians, Emergency Medicine Residents Association, Phi Beta Kappa, and Society for Academic Emergency Medicine

Disclosure: Nothing to disclose.

Barry E Brenner, MD, PhD, FACEP Professor of Emergency Medicine, Professor of Internal Medicine, Program Director, Emergency Medicine, Case Medical Center, University Hospitals, Case Western Reserve University School of Medicine

Barry E Brenner, MD, PhD, FACEP is a member of the following medical societies: Alpha Omega Alpha, American Academy of Emergency Medicine, American College of Chest Physicians, American College of Emergency Physicians, American College of Physicians, American Heart Association, American Thoracic Society, Arkansas Medical Society, New York Academy of Medicine, New York Academy of Sciences, and Society for Academic Emergency Medicine

Disclosure: Nothing to disclose.

Steven A Conrad, MD, PhD Chief, Department of Emergency Medicine; Chief, Multidisciplinary Critical Care Service, Professor, Department of Emergency and Internal Medicine, Louisiana State University Health Sciences Center

Steven A Conrad, MD, PhD is a member of the following medical societies: American College of Chest Physicians, American College of Critical Care Medicine, American College of Emergency Physicians, American College of Physicians, International Society for Heart and Lung Transplantation, Louisiana State Medical Society, Shock Society, Society for Academic Emergency Medicine, and Society of Critical Care Medicine

Disclosure: Nothing to disclose.

Brendan R Furlong, MD Clinical Chief, Department of Emergency Medicine, Georgetown University Hospital

Disclosure: Nothing to disclose.

Mary A Furlong, MD Associate Professor and Program/Residency Director, Department of Pathology, Georgetown University School of Medicine

Disclosure: Nothing to disclose.

Avishek Kumar, MD Resident Physician, Department of Internal Medicine, St Michael's Medical Center, Seton Hall University School of Health and Medical Sciences

Avishek Kumar, MD is a member of the following medical societies: American Medical Association

Disclosure: Nothing to disclose.

Pradyumna D Phatak, MBBS, MD Chair, Division of Hematology and Medical Oncology, Rochester General Hospital; Clinical Professor of Oncology, Roswell Park Cancer Institute

Pradyumna D Phatak, MBBS, MD, is a member of the following medical societies: American Society of Hematology

Disclosure: Novartis Honoraria Speaking and teaching

Ronald A Sacher, MB, BCh, MD, FRCPC Professor, Internal Medicine and Pathology, Director, Hoxworth Blood Center, University of Cincinnati Academic Health Center

Ronald A Sacher, MB, BCh, MD, FRCPC is a member of the following medical societies: American Association for the Advancement of Science, American Association of Blood Banks, American Clinical and Climatological Association, American Society for Clinical Pathology, American Society of Hematology, College of American Pathologists, International Society of Blood Transfusion, International Society on Thrombosis and Haemostasis, and Royal College of Physicians and Surgeons of Canada

Disclosure: Glaxo Smith Kline Honoraria Speaking and teaching; Talecris Honoraria Board membership

Hamid Salim Shaaban MD, Fellow in Hematology/ Oncology, Department of Internal Medicine, Seton Hall University School of Health and Medical Sciences

Hamid Salim Shaaban is a member of the following medical societies: American College of Physicians

Disclosure: Nothing to disclose.

Francisco Talavera, PharmD, PhD Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Medscape Salary Employment

Charles R Wira, MD Assistant Professor, Department of Surgery, Section of Emergency Medicine, Yale School of Medicine

Charles R Wira, MD is a member of the following medical societies: American College of Emergency Physicians, Society for Academic Emergency Medicine, and Society of Critical Care Medicine

Disclosure: Nothing to disclose.

References

  1. Costello RA, Nehring SM. Disseminated Intravascular Coagulation (DIC). 2018 Jan. [View Abstract]
  2. Vincent JL, De Backer D. Does disseminated intravascular coagulation lead to multiple organ failure?. Crit Care Clin. 2005 Jul. 21(3):469-77. [View Abstract]
  3. Papageorgiou C, Jourdi G, Adjambri E, Walborn A, Patel P, Fareed J, et al. Disseminated Intravascular Coagulation: An Update on Pathogenesis, Diagnosis, and Therapeutic Strategies. Clin Appl Thromb Hemost. 2018 Oct 8. 1076029618806424. [View Abstract]
  4. [Guideline] Taylor FB Jr, Toh CH, Hoots WK, Wada H, Levi M. Towards definition, clinical and laboratory criteria, and a scoring system for disseminated intravascular coagulation. Thromb Haemost. 2001 Nov. 86(5):1327-30. [View Abstract]
  5. Matsuda T. Clinical aspects of DIC--disseminated intravascular coagulation. Pol J Pharmacol. 1996 Jan-Feb. 48(1):73-5. [View Abstract]
  6. Levi M, de Jonge E, van der Poll T. New treatment strategies for disseminated intravascular coagulation based on current understanding of the pathophysiology. Ann Med. 2004. 36(1):41-9. [View Abstract]
  7. Branson HE, Katz J, Marble R, Griffin JH. Inherited protein C deficiency and coumarin-responsive chronic relapsing purpura fulminans in a newborn infant. Lancet. 1983 Nov 19. 2(8360):1165-8. [View Abstract]
  8. Yuen P, Cheung A, Lin HJ, Ho F, Mimuro J, Yoshida N, et al. Purpura fulminans in a Chinese boy with congenital protein C deficiency. Pediatrics. 1986 May. 77(5):670-6. [View Abstract]
  9. Asherson RA, Espinosa G, Cervera R, Gómez-Puerta JA, Musuruana J, Bucciarelli S, et al. Disseminated intravascular coagulation in catastrophic antiphospholipid syndrome: clinical and haematological characteristics of 23 patients. Ann Rheum Dis. 2005 Jun. 64(6):943-6. [View Abstract]
  10. Levi M, Sivapalaratnam S. Disseminated intravascular coagulation: an update on pathogenesis and diagnosis. Expert Rev Hematol. 2018 Aug. 11 (8):663-672. [View Abstract]
  11. Fourrier F, Chopin C, Goudemand J, Hendrycx S, Caron C, Rime A, et al. Septic shock, multiple organ failure, and disseminated intravascular coagulation. Compared patterns of antithrombin III, protein C, and protein S deficiencies. Chest. 1992 Mar. 101(3):816-23. [View Abstract]
  12. Gando S. Disseminated intravascular coagulation in trauma patients. Semin Thromb Hemost. 2001 Dec. 27(6):585-92. [View Abstract]
  13. Gando S, Nakanishi Y, Tedo I. Cytokines and plasminogen activator inhibitor-1 in posttrauma disseminated intravascular coagulation: relationship to multiple organ dysfunction syndrome. Crit Care Med. 1995 Nov. 23(11):1835-42. [View Abstract]
  14. Levi M. Disseminated intravascular coagulation: What's new?. Crit Care Clin. 2005 Jul. 21(3):449-67. [View Abstract]
  15. Franchini M, Lippi G, Manzato F. Recent acquisitions in the pathophysiology, diagnosis and treatment of disseminated intravascular coagulation. Thromb J. 2006 Feb 21. 4:4. [View Abstract]
  16. Levi M. Pathogenesis and diagnosis of disseminated intravascular coagulation. Int J Lab Hematol. 2018 May. 40 Suppl 1:15-20. [View Abstract]
  17. Levi M. The coagulant response in sepsis. Clin Chest Med. 2008 Dec. 29(4):627-42, viii. [View Abstract]
  18. Leblebisatan G, Sasmaz I, Antmen B, Yildizdas D, Kilinc Y. Management of life-threatening hemorrhages and unsafe interventions in nonhemophiliac children by recombinant factor VIIa. Clin Appl Thromb Hemost. 2010 Feb. 16(1):77-82. [View Abstract]
  19. Maczewski M, Duda M, Pawlak W, Beresewicz A. Endothelial protection from reperfusion injury by ischemic preconditioning and diazoxide involves a SOD-like anti-O2- mechanism. J Physiol Pharmacol. 2004 Sep. 55(3):537-50. [View Abstract]
  20. Levi M. Keep in contact: the role of the contact system in infection and sepsis. Crit Care Med. 2000 Nov. 28(11):3765-6. [View Abstract]
  21. Sower LE, Froelich CJ, Carney DH, Fenton JW 2nd, Klimpel GR. Thrombin induces IL-6 production in fibroblasts and epithelial cells. Evidence for the involvement of the seven-transmembrane domain (STD) receptor for alpha-thrombin. J Immunol. 1995 Jul 15. 155(2):895-901. [View Abstract]
  22. Taylor FB Jr, Chang A, Ruf W, Morrissey JH, Hinshaw L, Catlett R, et al. Lethal E. coli septic shock is prevented by blocking tissue factor with monoclonal antibody. Circ Shock. 1991 Mar. 33(3):127-34. [View Abstract]
  23. Levi M, ten Cate H, Bauer KA, van der Poll T, Edgington TS, Büller HR, et al. Inhibition of endotoxin-induced activation of coagulation and fibrinolysis by pentoxifylline or by a monoclonal anti-tissue factor antibody in chimpanzees. J Clin Invest. 1994 Jan. 93(1):114-20. [View Abstract]
  24. Carey MJ, Rodgers GM. Disseminated intravascular coagulation: clinical and laboratory aspects. Am J Hematol. 1998 Sep. 59(1):65-73. [View Abstract]
  25. Mesters RM, Mannucci PM, Coppola R, Keller T, Ostermann H, Kienast J. Factor VIIa and antithrombin III activity during severe sepsis and septic shock in neutropenic patients. Blood. 1996 Aug 1. 88(3):881-6. [View Abstract]
  26. Nawroth PP, Stern DM. Modulation of endothelial cell hemostatic properties by tumor necrosis factor. J Exp Med. 1986 Mar 1. 163(3):740-5. [View Abstract]
  27. Novotny WF, Brown SG, Miletich JP, Rader DJ, Broze GJ Jr. Plasma antigen levels of the lipoprotein-associated coagulation inhibitor in patient samples. Blood. 1991 Jul 15. 78(2):387-93. [View Abstract]
  28. Biemond BJ, Levi M, Ten Cate H, Van der Poll T, Büller HR, Hack CE, et al. Plasminogen activator and plasminogen activator inhibitor I release during experimental endotoxaemia in chimpanzees: effect of interventions in the cytokine and coagulation cascades. Clin Sci (Lond). 1995 May. 88(5):587-94. [View Abstract]
  29. van Hinsbergh VW, Kooistra T, van den Berg EA, Princen HM, Fiers W, Emeis JJ. Tumor necrosis factor increases the production of plasminogen activator inhibitor in human endothelial cells in vitro and in rats in vivo. Blood. 1988 Nov. 72(5):1467-73. [View Abstract]
  30. Mesters RM, Flörke N, Ostermann H, Kienast J. Increase of plasminogen activator inhibitor levels predicts outcome of leukocytopenic patients with sepsis. Thromb Haemost. 1996 Jun. 75(6):902-7. [View Abstract]
  31. Asakura H, Ontachi Y, Mizutani T, Kato M, Saito M, Kumabashiri I, et al. An enhanced fibrinolysis prevents the development of multiple organ failure in disseminated intravascular coagulation in spite of much activation of blood coagulation. Crit Care Med. 2001 Jun. 29(6):1164-8. [View Abstract]
  32. Levi M. Disseminated intravascular coagulation in cancer patients. Best Pract Res Clin Haematol. 2009 Mar. 22(1):129-36. [View Abstract]
  33. Levi M, van der Poll T, Büller HR. Bidirectional relation between inflammation and coagulation. Circulation. 2004 Jun 8. 109(22):2698-704. [View Abstract]
  34. Altieri DC. Molecular cloning of effector cell protease receptor-1, a novel cell surface receptor for the protease factor Xa. J Biol Chem. 1994 Feb 4. 269(5):3139-42. [View Abstract]
  35. Camerer E, Huang W, Coughlin SR. Tissue factor- and factor X-dependent activation of protease-activated receptor 2 by factor VIIa. Proc Natl Acad Sci U S A. 2000 May 9. 97(10):5255-60. [View Abstract]
  36. Erez O, Mastrolia SA, Thachil J. Disseminated intravascular coagulation in pregnancy: insights in pathophysiology, diagnosis and management. Am J Obstet Gynecol. 2015 Oct. 213 (4):452-463. [View Abstract]
  37. [Guideline] Levi M, Toh CH, Thachil J, Watson HG. Guidelines for the diagnosis and management of disseminated intravascular coagulation. British Committee for Standards in Haematology. Br J Haematol. 2009 Apr. 145(1):24-33. [View Abstract]
  38. Umemura Y, Yamakawa K, Kiguchi T, Yoshikawa Y, Ogura H, et al. Design and Evaluation of New Unified Criteria for Disseminated Intravascular Coagulation Based on the Japanese Association for Acute Medicine Criteria. Clin Appl Thromb Hemost. 2015 Jun 13. [View Abstract]
  39. Sawamura A, Hayakawa M, Gando S, Kubota N, Sugano M, Wada T, et al. Disseminated intravascular coagulation with a fibrinolytic phenotype at an early phase of trauma predicts mortality. Thromb Res. 2009 Nov. 124(5):608-13. [View Abstract]
  40. Sivula M, Pettilä V, Niemi TT, Varpula M, Kuitunen AH. Thromboelastometry in patients with severe sepsis and disseminated intravascular coagulation. Blood Coagul Fibrinolysis. 2009 Sep. 20(6):419-26. [View Abstract]
  41. Sawamura A, Hayakawa M, Gando S, Kubota N, Sugano M, Wada T, et al. Application of the Japanese Association for Acute Medicine disseminated intravascular coagulation diagnostic criteria for patients at an early phase of trauma. Thromb Res. 2009 Dec. 124(6):706-10. [View Abstract]
  42. Zhu YJ, Huang XK. Relationship between disseminated intravascular coagulation and levels of plasma thrombinogen segment 1+2, D-dimer, and thrombomodulin in patients with multiple injuries. Chin J Traumatol. 2009 Aug. 12(4):203-9. [View Abstract]
  43. Duchesne JC, Islam TM, Stuke L, Timmer JR, Barbeau JM, Marr AB, et al. Hemostatic resuscitation during surgery improves survival in patients with traumatic-induced coagulopathy. J Trauma. 2009 Jul. 67(1):33-7; discussion 37-9. [View Abstract]
  44. Siegal T, Seligsohn U, Aghai E, Modan M. Clinical and laboratory aspects of disseminated intravascular coagulation (DIC): a study of 118 cases. Thromb Haemost. 1978 Feb 28. 39(1):122-34. [View Abstract]
  45. Wada H, Mori Y, Shimura M, Hiyoyama K, Ioka M, Nakasaki T, et al. Poor outcome in disseminated intravascular coagulation or thrombotic thrombocytopenic purpura patients with severe vascular endothelial cell injuries. Am J Hematol. 1998 Jul. 58(3):189-94. [View Abstract]
  46. Takashima A, Shirao K, Hirashima Y, Takahari D, Okita NT, Nakajima TE, et al. Sequential chemotherapy with methotrexate and 5-fluorouracil for chemotherapy-naive advanced gastric cancer with disseminated intravascular coagulation at initial diagnosis. J Cancer Res Clin Oncol. 2010 Feb. 136(2):243-8. [View Abstract]
  47. Bick RL. Disseminated intravascular coagulation: objective clinical and laboratory diagnosis, treatment, and assessment of therapeutic response. Semin Thromb Hemost. 1996. 22(1):69-88. [View Abstract]
  48. Horan JT, Francis CW. Fibrin degradation products, fibrin monomer and soluble fibrin in disseminated intravascular coagulation. Semin Thromb Hemost. 2001 Dec. 27(6):657-66. [View Abstract]
  49. Leung L. Clinical features, diagnosis, and treatment of disseminated intravascular coagulation in adults. UpToDate [serial online]. Available at . Available at http://www.utdol.com
  50. Spero JA, Lewis JH, Hasiba U. Disseminated intravascular coagulation. Findings in 346 patients. Thromb Haemost. 1980 Feb 29. 43(1):28-33. [View Abstract]
  51. Olson JD, Kaufman HH, Moake J, O'Gorman TW, Hoots K, Wagner K, et al. The incidence and significance of hemostatic abnormalities in patients with head injuries. Neurosurgery. 1989 Jun. 24(6):825-32. [View Abstract]
  52. Conway EM, Rosenberg RD. Tumor necrosis factor suppresses transcription of the thrombomodulin gene in endothelial cells. Mol Cell Biol. 1988 Dec. 8(12):5588-92. [View Abstract]
  53. Faust SN, Levin M, Harrison OB, Goldin RD, Lockhart MS, Kondaveeti S, et al. Dysfunction of endothelial protein C activation in severe meningococcal sepsis. N Engl J Med. 2001 Aug 9. 345(6):408-16. [View Abstract]
  54. Downey C, Kazmi R, Toh CH. Novel and diagnostically applicable information from optical waveform analysis of blood coagulation in disseminated intravascular coagulation. Br J Haematol. 1997 Jul. 98(1):68-73. [View Abstract]
  55. Dempfle CE. The use of soluble fibrin in evaluating the acute and chronic hypercoagulable state. Thromb Haemost. 1999 Aug. 82(2):673-83. [View Abstract]
  56. Levi M, de Jonge E, van der Poll T, ten Cate H. Disseminated intravascular coagulation. Thromb Haemost. 1999 Aug. 82(2):695-705. [View Abstract]
  57. Carr JM, McKinney M, McDonagh J. Diagnosis of disseminated intravascular coagulation. Role of D-dimer. Am J Clin Pathol. 1989 Mar. 91(3):280-7. [View Abstract]
  58. Levi M, Meijers JC. DIC: which laboratory tests are most useful. Blood Rev. 2011 Jan. 25(1):33-7. [View Abstract]
  59. Lin SM, Wang YM, Lin HC, Lee KY, Huang CD, Liu CY, et al. Serum thrombomodulin level relates to the clinical course of disseminated intravascular coagulation, multiorgan dysfunction syndrome, and mortality in patients with sepsis. Crit Care Med. 2008 Mar. 36(3):683-9. [View Abstract]
  60. Bakhtiari K, Meijers JC, de Jonge E, Levi M. Prospective validation of the International Society of Thrombosis and Haemostasis scoring system for disseminated intravascular coagulation. Crit Care Med. 2004 Dec. 32(12):2416-21. [View Abstract]
  61. Gando S, Saitoh D, Ogura H, Mayumi T, Koseki K, Ikeda T, et al. Natural history of disseminated intravascular coagulation diagnosed based on the newly established diagnostic criteria for critically ill patients: results of a multicenter, prospective survey. Crit Care Med. 2008 Jan. 36(1):145-50. [View Abstract]
  62. [Guideline] Wada H, Matsumoto T, Yamashita Y. Diagnosis and treatment of disseminated intravascular coagulation (DIC) according to four DIC guidelines. J Intensive Care. 2014. 2 (1):15. [View Abstract]
  63. Levi M, Scully M. How I treat disseminated intravascular coagulation. Blood. 2018 Feb 22. 131 (8):845-854. [View Abstract]
  64. Lowes R. Sepsis Drug Xigris Pulled From Worldwide Market. Medscape Medical News. Available at http://www.medscape.com/viewarticle/752169. Accessed: April 14, 2014.
  65. [Guideline] Di Nisio M, Baudo F, Cosmi B, D'Angelo A, De Gasperi A, Malato A, et al. Diagnosis and treatment of disseminated intravascular coagulation: guidelines of the Italian Society for Haemostasis and Thrombosis (SISET). Thromb Res. 2012 May. 129 (5):e177-84. [View Abstract]
  66. Levi M, Opal SM. Coagulation abnormalities in critically ill patients. Crit Care. 2006. 10(4):222. [View Abstract]
  67. Alving B, Spivak J, Deloughery T. Consultative hematology: Hemostasis and transfusion issues in surgery and critical care medicine. Hematology. 1998. 320-42.
  68. [Guideline] Wada H, Asakura H, Okamoto K, Iba T, Uchiyama T, Kawasugi K, et al. Expert consensus for the treatment of disseminated intravascular coagulation in Japan. Thromb Res. 2010 Jan. 125(1):6-11. [View Abstract]
  69. Pernerstorfer T, Jilma B, Eichler HG, Aull S, Handler S, Speiser W. Heparin lowers plasma levels of activated factor VII. Br J Haematol. 1999 Jun. 105(4):1127-9. [View Abstract]
  70. Feinstein DI. Diagnosis and management of disseminated intravascular coagulation: the role of heparin therapy. Blood. 1982 Aug. 60(2):284-7. [View Abstract]
  71. Sakuragawa N, Hasegawa H, Maki M, Nakagawa M, Nakashima M. Clinical evaluation of low-molecular-weight heparin (FR-860) on disseminated intravascular coagulation (DIC)--a multicenter co-operative double-blind trial in comparison with heparin. Thromb Res. 1993 Dec 15. 72(6):475-500. [View Abstract]
  72. Pernerstorfer T, Hollenstein U, Hansen J, Knechtelsdorfer M, Stohlawetz P, Graninger W, et al. Heparin blunts endotoxin-induced coagulation activation. Circulation. 1999 Dec 21-28. 100(25):2485-90. [View Abstract]
  73. Majumdar G. Idiopathic chronic DIC controlled with low-molecular-weight heparin. Blood Coagul Fibrinolysis. 1996 Jan. 7(1):97-8. [View Abstract]
  74. Levi M, Levy M, Williams MD, Douglas I, Artigas A, Antonelli M, et al. Prophylactic heparin in patients with severe sepsis treated with drotrecogin alfa (activated). Am J Respir Crit Care Med. 2007 Sep 1. 176(5):483-90. [View Abstract]
  75. Baudo F, Caimi TM, de Cataldo F, Ravizza A, Arlati S, Casella G, et al. Antithrombin III (ATIII) replacement therapy in patients with sepsis and/or postsurgical complications: a controlled double-blind, randomized, multicenter study. Intensive Care Med. 1998 Apr. 24(4):336-42. [View Abstract]
  76. Fourrier F, Jourdain M, Tournoys A. Clinical trial results with antithrombin III in sepsis. Crit Care Med. 2000 Sep. 28(9 Suppl):S38-43. [View Abstract]
  77. Eisele B, Lamy M, Thijs LG, Keinecke HO, Schuster HP, Matthias FR, et al. Antithrombin III in patients with severe sepsis. A randomized, placebo-controlled, double-blind multicenter trial plus a meta-analysis on all randomized, placebo-controlled, double-blind trials with antithrombin III in severe sepsis. Intensive Care Med. 1998 Jul. 24(7):663-72. [View Abstract]
  78. Sawamura A, Gando S, Hayakawa M, Hoshino H, Kubota N, Sugano M. Effects of antithrombin III in patients with disseminated intravascular coagulation diagnosed by newly developed diagnostic criteria for critical illness. Clin Appl Thromb Hemost. 2009 Oct. 15(5):561-6. [View Abstract]
  79. Hayakawa M, Kudo D, Saito S, et al. Antithrombin Supplementation and Mortality in Sepsis-Induced Disseminated Intravascular Coagulation: A Multicenter Retrospective Observational Study. Shock. 2016 Aug 19. [View Abstract]
  80. Endo S, Shimazaki R, Antithrombin Gamma Study Group. An open-label, randomized, phase 3 study of the efficacy and safety of antithrombin gamma in patients with sepsis-induced disseminated intravascular coagulation syndrome. J Intensive Care. 2018. 6:75. [View Abstract]
  81. Abraham E. Tissue factor inhibition and clinical trial results of tissue factor pathway inhibitor in sepsis. Crit Care Med. 2000 Sep. 28(9 Suppl):S31-3. [View Abstract]
  82. Abraham E, Reinhart K, Opal S, Demeyer I, Doig C, Rodriguez AL, et al. Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: a randomized controlled trial. JAMA. 2003 Jul 9. 290(2):238-47. [View Abstract]
  83. Yamakawa K, Fujimi S, Mohri T, Matsuda H, Nakamori Y, Hirose T, et al. Treatment effects of recombinant human soluble thrombomodulin in patients with severe sepsis: a historical control study. Crit Care. 2011. 15(3):R123. [View Abstract]
  84. Saito H, Maruyama I, Shimazaki S, Yamamoto Y, Aikawa N, Ohno R, et al. Efficacy and safety of recombinant human soluble thrombomodulin (ART-123) in disseminated intravascular coagulation: results of a phase III, randomized, double-blind clinical trial. J Thromb Haemost. 2007 Jan. 5(1):31-41. [View Abstract]
  85. Zhang C, Wang H, Yang H, Tong Z. Recombinant human soluble thrombomodulin and short-term mortality of infection patients with DIC: a meta-analysis. Am J Emerg Med. 2016 Sep. 34 (9):1876-82. [View Abstract]
  86. Yamakawa K, Aihara M, Ogura H, Yuhara H, Hamasaki T, Shimazu T. Recombinant human soluble thrombomodulin in severe sepsis: a systematic review and meta-analysis. J Thromb Haemost. 2015 Apr. 13 (4):508-19. [View Abstract]
  87. Inoue Y, Matsunawa M, Sano F, Miura I. Efficacy of Recombinant Human Soluble Thrombomodulin in Treating Disseminated Intravascular Coagulation Complicating Allogeneic Hematopoietic Stem Cell Transplantation. Acta Haematol. 2018 Sep 18. 140 (2):121-127. [View Abstract]
  88. Levi M. Current understanding of disseminated intravascular coagulation. Br J Haematol. 2004 Mar. 124(5):567-76. [View Abstract]
  89. Norman KE, Cotter MJ, Stewart JB, Abbitt KB, Ali M, Wagner BE, et al. Combined anticoagulant and antiselectin treatments prevent lethal intravascular coagulation. Blood. 2003 Feb 1. 101(3):921-8. [View Abstract]
  90. Pajkrt D, van der Poll T, Levi M, Cutler DL, Affrime MB, van den Ende A, et al. Interleukin-10 inhibits activation of coagulation and fibrinolysis during human endotoxemia. Blood. 1997 Apr 15. 89(8):2701-5. [View Abstract]
  91. Branger J, van den Blink B, Weijer S, Gupta A, van Deventer SJ, Hack CE, et al. Inhibition of coagulation, fibrinolysis, and endothelial cell activation by a p38 mitogen-activated protein kinase inhibitor during human endotoxemia. Blood. 2003 Jun 1. 101(11):4446-8. [View Abstract]
  92. Baratto F, Michielan F, Meroni M, Dal Palù A, Boscolo A, Ori C. Protein C concentrate to restore physiological values in adult septic patients. Intensive Care Med. 2008 Sep. 34(9):1707-12. [View Abstract]
  93. Shakur H, Roberts I, Bautista R, Caballero J, Coats T, Dewan Y, et al. Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial. Lancet. 2010 Jul 3. 376(9734):23-32. [View Abstract]
  94. Ducloy-Bouthors AS, Jude B, Duhamel A, Broisin F, Huissoud C, Keita-Meyer H. High-dose tranexamic acid reduces blood loss in postpartum haemorrhage. Crit Care. 2011. 15(2):R117. [View Abstract]
  95. Sohn CH, Kim SR, Kim YJ, Seo DW, Ahn S, Lee YS, et al. Disseminated Intravascular Coagulation in Emergency Department Patients With Primary Postpartum Hemorrhage. Shock. 2017 Sep. 48 (3):329-332. [View Abstract]
  96. Costello RA, Nehring SM. Disseminated Intravascular Coagulation (DIC). 2017 Jun. [View Abstract]
  97. Wada H, Matsumoto T, Suzuki K, Imai H, Katayama N, Iba T, et al. Differences and similarities between disseminated intravascular coagulation and thrombotic microangiopathy. Thromb J. 2018. 16:14. [View Abstract]
  98. [Guideline] Wada H, Matsumoto T, Hatada T. Diagnostic criteria and laboratory tests for disseminated intravascular coagulation. Expert Rev Hematol. 2012 Dec. 5 (6):643-52. [View Abstract]

Diagnostic algorithm for the diagnosis of overt disseminated intravascular coagulation.

Diagnostic algorithm for the diagnosis of overt disseminated intravascular coagulation.

Coagulation pathway.

Type Cause
InfectiousBacterial (eg, gram-negative sepsis, gram-positive infections, rickettsial)



Viral (eg, HIV, cytomegalovirus [CMV], varicella-zoster virus [VZV], and hepatitis virus)



Fungal (eg, Histoplasma)



Parasitic (eg, malaria)



MalignancyHematologic (eg, acute myelocytic leukemia)



Metastatic (eg, mucin-secreting adenocarcinoma)



ObstetricAmniotic fluid embolism



Abruptio placentae



Acute peripartum hemorrhage



Preeclampsia/eclampsia/hemolysis, elevated liver enzymes, and low platelet count (HELLP) syndrome



Retained stillbirth



Septic abortion and intrauterine infection



Acute fatty liver of pregnancy[36]



TraumaBurns



Motor vehicle accidents



Snake envenomation



TransfusionHemolytic reactions



Transfusion



OtherLiver disease/acute hepatic failure*



Prosthetic devices



Shunts (Denver or LeVeen)



Ventricular assist devices



*Some do not classify this as DIC; rather, it is liver disease with reduced blood coagulation factor synthesis and reduced clearance of activate products of coagulation.
Type Cause
MalignanciesSolid tumors



Leukemia



ObstetricRetained dead fetus syndrome



Retained products of conception



HematologicMyeloproliferative syndromes
VascularRheumatoid arthritis



Raynaud disease



CardiovascularMyocardial infarction
InflammatoryUlcerative colitis



Crohn disease



Sarcoidosis



Localized DICAortic aneurysms



Giant hemangioma (Kasabach-Merritt syndrome)



Acute renal allograft rejection



Features Affected Patients, %
Bleeding64%
Renal dysfunction25%
Hepatic dysfunction19%
Respiratory dysfunction16%
Shock14%
Central nervous system dysfunction2%
Clinical conditions that should be ruled out
Thrombocytopenia



Dilution and abnormal distribution



Massive blood loss, massive infusion



ITP, TTP-HUS, HIT, HELLP syndrome



Disorders of hematopoiesis



Liver disease



Hypothermia



Spurious laboratory results



Diagnostic algorithm for SIRS
Temperature >38°C or < 36°C



Heart rate >90 beats/min



Respiratory rate >20 breaths/min or PaCO2< 32 mm Hg (< 4.3 kPa)



WBC count >12,000 cells/µL, < 4000 cells/ µL, or 10% immature (band) forms



Diagnostic algorithm



SIRS criteria



Score
>31
0-20
Platelet count (× 109/L) 
< 80 or >50 % decrease within 24 hours3
>80 and < 120 or >30% decrease within 24 hours1
>1200
Prothrombin time (value of patient/normal value)  
>1.21
< 1.20
Fibrin/FDPs (mg/L)  
>253
>10 and < 251
< 100
Diagnosis



4 points or more



DIC
DIC = disseminated intravascular coagulation; FDP = fibrin degradation product; HELLP = hemolysis, elevated liver enzymes, low platelet count; HIT = heparin-induced thrombocytopenia; HUS = hemolytic uremic syndrome; ITP = idiopathic thrombocytopenic purpura; PaCO2 = partial pressure of carbon dioxide in arterial blood; SIRS = systemic inflammatory response syndrome; TTP = thrombotic thrombocytopenic purpura; WBC = white blood cell.